We estimate that the CEO of Viridian Therapeutics, Inc.\DE ($VRDN), Stephen Mahoney, received a compensation of $6,776,249 in 2025. This is an increase of 83.51% from an estimated $1,117,454 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 17, 2026. Note that parsing errors may occur.
You can track $VRDN on Quiver Quantitative's $VRDN stock dashboard.
$VRDN Stock Insider Trading Activity
$VRDN Stock insiders have traded $VRDN stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VRDN stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 454,545 shares for an estimated $9,999,990
- JENNIFER TOUSIGNANT (Chief Legal Officer) sold 2,272 shares for an estimated $70,795
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VRDN Stock Hedge Fund Activity
We have seen 152 institutional investors add shares of $VRDN Stock stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BELLEVUE GROUP AG added 4,358,527 shares (+inf%) to their portfolio in Q4 2025, for an estimated $135,637,360
- COMMODORE CAPITAL LP removed 3,200,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $99,584,000
- KYNAM CAPITAL MANAGEMENT, LP removed 2,957,386 shares (-66.8%) from their portfolio in Q4 2025, for an estimated $92,033,852
- DEEP TRACK CAPITAL, LP removed 2,855,616 shares (-53.1%) from their portfolio in Q4 2025, for an estimated $88,866,769
- MAVERICK CAPITAL LTD removed 2,212,701 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $68,859,255
- FMR LLC added 2,135,101 shares (+17.4%) to their portfolio in Q4 2025, for an estimated $66,444,343
- PERCEPTIVE ADVISORS LLC added 1,580,303 shares (+108.1%) to their portfolio in Q4 2025, for an estimated $49,179,029
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VRDN Stock Analyst Ratings
Wall Street analysts have issued reports on $VRDN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/04/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- UBS issued a "Buy" rating on 01/07/2026
- William Blair issued a "Outperform" rating on 12/03/2025
- RBC Capital issued a "Outperform" rating on 11/06/2025
- BTIG issued a "Buy" rating on 11/04/2025
- Oppenheimer issued a "Outperform" rating on 10/21/2025
To track analyst ratings and price targets for $VRDN Stock, check out Quiver Quantitative's $VRDN forecast page.
$VRDN Stock Price Targets
Multiple analysts have issued price targets for $VRDN recently. We have seen 11 analysts offer price targets for $VRDN in the last 6 months, with a median target of $32.0.
Here are some recent targets:
- Laura Chico from Wedbush set a target price of $31.0 on 04/08/2026
- Lisa Walter from RBC Capital set a target price of $30.0 on 04/07/2026
- Richard Law from Goldman Sachs set a target price of $31.0 on 04/07/2026
- Maneka Mirchandaney from Evercore ISI Group set a target price of $32.0 on 04/02/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $22.0 on 03/31/2026
- Derek Archila from Wells Fargo set a target price of $20.0 on 03/31/2026
- Serge Belanger from Needham set a target price of $32.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
